The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The diabetes prevention program randomized trial

Trevor J. Orchard, Marinella Temprosa, Ronald B Goldberg, Steven Haffner, Robert Ratner, Santica Marcovina, Sarah Fowler

Research output: Contribution to journalArticle

698 Citations (Scopus)

Abstract

Background: The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. Objective: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution. Design: Randomized, controlled clinical trial. Setting: Research and community-based centers. Participants: Participants had impaired glucose tolerance (World Health Organization criteria plus fasting plasma glucose level ≥5.3 mmol/L [≥95 mg/dL]) and were followed for a mean of 3.2 years after random assignment to intensive lifestyle intervention, metformin therapy, or placebo. Interventions: Metformin, 850 mg twice daily, or intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week. Measurements: The metabolic syndrome was defined as having 3 or more characteristics (waist circumference; blood pressure; and levels of high-density lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the National Cholesterol Education Program Adult Treatment Panel III. Results: Fifty-three percent of participants (n = 1711) had the metabolic syndrome at baseline; incidence did not vary substantially by age. However, low levels of high-density lipoprotein cholesterol predominated in younger participants (age 25 to 44 years), and high blood pressure predominated in older participants (age 60 to 82 years). In life-table analyses (log-rank test), incidence of the metabolic syndrome was reduced by 41% in the lifestyle group (P < 0.001) and by 17% in the metformin group (P = 0.03) compared with placebo. Three-year cumulative incidences were 51%, 45%, and 34% in the placebo, metformin, and lifestyle groups, respectively. There was no significant heterogeneity by ethnic group. Limitations: The study involved a volunteer group with impaired glucose tolerance, which limits generalizability. Conclusions: The metabolic syndrome affected approximately half of the participants in the Diabetes Prevention Program at baseline. Both lifestyle intervention and metformin therapy reduced the development of the syndrome in the remaining participants.

Original languageEnglish
Pages (from-to)611-619
Number of pages9
JournalAnnals of Internal Medicine
Volume142
Issue number8
StatePublished - Apr 19 2005
Externally publishedYes

Fingerprint

Metformin
Life Style
Glucose Intolerance
Incidence
Placebos
HDL Cholesterol
Fasting
Glucose
Life Tables
Waist Circumference
Therapeutics
Ethnic Groups
Weight Loss
Volunteers
Triglycerides
Cardiovascular Diseases
Randomized Controlled Trials
Cholesterol
Exercise
Blood Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome : The diabetes prevention program randomized trial. / Orchard, Trevor J.; Temprosa, Marinella; Goldberg, Ronald B; Haffner, Steven; Ratner, Robert; Marcovina, Santica; Fowler, Sarah.

In: Annals of Internal Medicine, Vol. 142, No. 8, 19.04.2005, p. 611-619.

Research output: Contribution to journalArticle

Orchard, Trevor J. ; Temprosa, Marinella ; Goldberg, Ronald B ; Haffner, Steven ; Ratner, Robert ; Marcovina, Santica ; Fowler, Sarah. / The effect of metformin and intensive lifestyle intervention on the metabolic syndrome : The diabetes prevention program randomized trial. In: Annals of Internal Medicine. 2005 ; Vol. 142, No. 8. pp. 611-619.
@article{f0272e375399479da09d062742d7773e,
title = "The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The diabetes prevention program randomized trial",
abstract = "Background: The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. Objective: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution. Design: Randomized, controlled clinical trial. Setting: Research and community-based centers. Participants: Participants had impaired glucose tolerance (World Health Organization criteria plus fasting plasma glucose level ≥5.3 mmol/L [≥95 mg/dL]) and were followed for a mean of 3.2 years after random assignment to intensive lifestyle intervention, metformin therapy, or placebo. Interventions: Metformin, 850 mg twice daily, or intensive lifestyle intervention designed to achieve and maintain a 7{\%} weight loss and 150 minutes of exercise per week. Measurements: The metabolic syndrome was defined as having 3 or more characteristics (waist circumference; blood pressure; and levels of high-density lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the National Cholesterol Education Program Adult Treatment Panel III. Results: Fifty-three percent of participants (n = 1711) had the metabolic syndrome at baseline; incidence did not vary substantially by age. However, low levels of high-density lipoprotein cholesterol predominated in younger participants (age 25 to 44 years), and high blood pressure predominated in older participants (age 60 to 82 years). In life-table analyses (log-rank test), incidence of the metabolic syndrome was reduced by 41{\%} in the lifestyle group (P < 0.001) and by 17{\%} in the metformin group (P = 0.03) compared with placebo. Three-year cumulative incidences were 51{\%}, 45{\%}, and 34{\%} in the placebo, metformin, and lifestyle groups, respectively. There was no significant heterogeneity by ethnic group. Limitations: The study involved a volunteer group with impaired glucose tolerance, which limits generalizability. Conclusions: The metabolic syndrome affected approximately half of the participants in the Diabetes Prevention Program at baseline. Both lifestyle intervention and metformin therapy reduced the development of the syndrome in the remaining participants.",
author = "Orchard, {Trevor J.} and Marinella Temprosa and Goldberg, {Ronald B} and Steven Haffner and Robert Ratner and Santica Marcovina and Sarah Fowler",
year = "2005",
month = "4",
day = "19",
language = "English",
volume = "142",
pages = "611--619",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "8",

}

TY - JOUR

T1 - The effect of metformin and intensive lifestyle intervention on the metabolic syndrome

T2 - The diabetes prevention program randomized trial

AU - Orchard, Trevor J.

AU - Temprosa, Marinella

AU - Goldberg, Ronald B

AU - Haffner, Steven

AU - Ratner, Robert

AU - Marcovina, Santica

AU - Fowler, Sarah

PY - 2005/4/19

Y1 - 2005/4/19

N2 - Background: The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. Objective: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution. Design: Randomized, controlled clinical trial. Setting: Research and community-based centers. Participants: Participants had impaired glucose tolerance (World Health Organization criteria plus fasting plasma glucose level ≥5.3 mmol/L [≥95 mg/dL]) and were followed for a mean of 3.2 years after random assignment to intensive lifestyle intervention, metformin therapy, or placebo. Interventions: Metformin, 850 mg twice daily, or intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week. Measurements: The metabolic syndrome was defined as having 3 or more characteristics (waist circumference; blood pressure; and levels of high-density lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the National Cholesterol Education Program Adult Treatment Panel III. Results: Fifty-three percent of participants (n = 1711) had the metabolic syndrome at baseline; incidence did not vary substantially by age. However, low levels of high-density lipoprotein cholesterol predominated in younger participants (age 25 to 44 years), and high blood pressure predominated in older participants (age 60 to 82 years). In life-table analyses (log-rank test), incidence of the metabolic syndrome was reduced by 41% in the lifestyle group (P < 0.001) and by 17% in the metformin group (P = 0.03) compared with placebo. Three-year cumulative incidences were 51%, 45%, and 34% in the placebo, metformin, and lifestyle groups, respectively. There was no significant heterogeneity by ethnic group. Limitations: The study involved a volunteer group with impaired glucose tolerance, which limits generalizability. Conclusions: The metabolic syndrome affected approximately half of the participants in the Diabetes Prevention Program at baseline. Both lifestyle intervention and metformin therapy reduced the development of the syndrome in the remaining participants.

AB - Background: The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. Objective: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution. Design: Randomized, controlled clinical trial. Setting: Research and community-based centers. Participants: Participants had impaired glucose tolerance (World Health Organization criteria plus fasting plasma glucose level ≥5.3 mmol/L [≥95 mg/dL]) and were followed for a mean of 3.2 years after random assignment to intensive lifestyle intervention, metformin therapy, or placebo. Interventions: Metformin, 850 mg twice daily, or intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week. Measurements: The metabolic syndrome was defined as having 3 or more characteristics (waist circumference; blood pressure; and levels of high-density lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the National Cholesterol Education Program Adult Treatment Panel III. Results: Fifty-three percent of participants (n = 1711) had the metabolic syndrome at baseline; incidence did not vary substantially by age. However, low levels of high-density lipoprotein cholesterol predominated in younger participants (age 25 to 44 years), and high blood pressure predominated in older participants (age 60 to 82 years). In life-table analyses (log-rank test), incidence of the metabolic syndrome was reduced by 41% in the lifestyle group (P < 0.001) and by 17% in the metformin group (P = 0.03) compared with placebo. Three-year cumulative incidences were 51%, 45%, and 34% in the placebo, metformin, and lifestyle groups, respectively. There was no significant heterogeneity by ethnic group. Limitations: The study involved a volunteer group with impaired glucose tolerance, which limits generalizability. Conclusions: The metabolic syndrome affected approximately half of the participants in the Diabetes Prevention Program at baseline. Both lifestyle intervention and metformin therapy reduced the development of the syndrome in the remaining participants.

UR - http://www.scopus.com/inward/record.url?scp=17144389303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144389303&partnerID=8YFLogxK

M3 - Article

C2 - 15838067

AN - SCOPUS:17144389303

VL - 142

SP - 611

EP - 619

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 8

ER -